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Background
The growth of a personalised approach to cancer treatment
including surgical risk management strategies and Parp
Inhibitor trials for BRCA1/2 mutation carriers has lead to
the Peter MacCallum Familial Cancer Centre experiencing
a rapidly increased demand for expedited risk assessment
appointments +/- BRCA1/2 mutation testing.
Expedited BRCA mutation screens are offered to indi-
viduals assessed eligible for publically funded testing and
require these results in a defined time period to assist in
their current cancer management.
The demand for expedited services places a burden on
both the laboratory and clinic as patients need to be
seen at short notice and have their genetic test take
priority over routine tests.
Aim
To better understand the clinical utility and mutation
detection rate of expedited BRCA1/2 tests, in order to
improve services and resources for this group of patients.
Methods
A retrospective review of the Peter MacCallum Familial
Cancer Centre’s BRCA1/2 mutation testing data from
January 2007-April 2011 was performed. During this
time period 119 patients were offered a treatment-
focussed genetic test. The characteristics of the tested
cohort were reviewed and analysed.
Results
Numbers of referrals for expedited risk assessment and
requests for treatment focussed BRCA1/2 mutation test-
ing remained consistent between 2007 and 2009
although have significantly increased in 2010 with nearly
a twofold increase.
Most patients referred had been recently diagnosed
with breast cancer and were considering the option of
breast conservation versus mastectomy. To assist them
with this decision they were seeking advice about their
genetic risk of developing a new primary breast cancer.
In addition, referrals were also received to determine
the eligibility of some patients for Parp Inhibitor trials.
A pathogenic mutation was detected in 20/119
(16.8per cent) of patients who had an expedited
BRCA1/2 test. Further analysis about the pre and post
testing treatment decisions is being analysed and will be
presented.
Conclusion
In 2010 a significant increase in demand for treatment
focussed risk assessments and expedited BRCA1/2 tests
was experienced by the Peter MacCallum Familial Can-
cer Centre. Further data will be presented on the char-
acteristics of these cohorts and the clinical utility of
expedited assessments.
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